SCHEMBL4260893

SCHEMBL4260893

Cc1cc(Cl)ccc1C(=O)NS(=O)(=O)C=Cc1csc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 8/20 0.47
FLT4 P35916 8/20 0.47
KDR P35968 8/20 0.47
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
MAOB P27338 3/20 0.42
GPR27 Q9NS67 1/20 0.41
CMA1 P23946 2/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38
TUBB8 Q3ZCM7 1/20 0.38
TUBA3E Q6PEY2 1/20 0.38
TUBA1A Q71U36 1/20 0.38
TUBA1C Q9BQE3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4260884 1.00 FLT1 (0.47) FLT1FLT4KDRPTGS1PTGS2
SCHEMBL4260392 0.89 FLT1 (0.49) FLT1FLT4KDRMAOB
SCHEMBL4260386 0.89 FLT1 (0.49) FLT1FLT4KDRMAOB
SCHEMBL4260886 0.82 PTGS1 (0.46) FLT1FLT4KDRPTGS1PTGS2
SCHEMBL5420993 0.82 FLT1 (0.53) FLT1FLT4KDRGPR27CYP11B2
SCHEMBL5421004 0.82 FLT1 (0.53) FLT1FLT4KDRGPR27CYP11B2
SCHEMBL4256644 0.81 KMT2A (0.41) FLT1FLT4KDRPTGS1PTGS2
SCHEMBL4256607 0.81 KMT2A (0.41) FLT1FLT4KDRPTGS1PTGS2
SCHEMBL5415477 0.80 FLT1 (0.55) FLT1FLT4KDRGPR27CYP11B2
SCHEMBL5415462 0.80 FLT1 (0.55) FLT1FLT4KDRGPR27CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP claimed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP disclosed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP1A1, CYP3A5 FLT1 2692/4885FLT4 2521/4885KDR 1957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.